TNO155 drug page Clinical trials

Trials with TNO155

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

5Trials
0Recruiting
18Countries
1.284Planned patients

Showing 1–5 of 5

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Ongoing, not recruiting Phase 1 344 patients NCT04699188

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced solid tumor pa…

United States, Australia, Belgium, Canada and 7 more Feb 2021 – Jan 2027 Interventional
Combined with: JDQ443Tislelizumab
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Ongoing, not recruiting Phase 1 610 patients NCT04185883

To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.

United States, Australia, Austria, Belgium and 6 more Dec 2019 – Dec 2027 Interventional
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
Finished Phase 1 122 patients NCT04294160

A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.

United States, Australia, Belgium, Canada and 6 more Jul 2020 – Sept 2024 Interventional
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Finished Phase 1 86 patients NCT04330664

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation.

United States Apr 2020 – Feb 2025 Interventional
Combined with: Adagrasib
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Finished Phase 1 122 patients NCT04000529

This study was a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors. These two trea…

United States, Australia, Belgium, China and 5 more Jul 2019 – Jan 2024 Interventional
Combined with: RibociclibSpartalizumab